UK market access

News

Sanofi’s blockbuster-tipped Dupixent set for European launch...

Sanofi’s new atopic dermatitis treatment Dupixent has gained EU approval, setting it up for a launch across key European markets.

News

After a year's delay, BMS seals Opdivo lung cancer deal with...

Bristol-Myers Squibb will now challenge its rival, MSD's Keytruda, in second line lung cancer treatment in England after it agreed a 'managed access' deal with NICE.

News

Roche hails 4 year NICE access deal for Gazyvaro

NICE has agreed a deal with Roche on its new follicular lymphoma treatment Gazyvaro, giving the dru

Views & Analysis

Patient on hospital bed with saline solution tube

Will UK patients get access to novel drugs?

Access to new medicines is not high up the list of priorities for NHS England, but pharma must seize opportunities to promote innovation uptake.

News

Lilly’s sarcoma drug Lartruvo recommended via Cancer Drugs F...

Lilly's drug will be re-appraised in 2020

News

Amgen’s myeloma treatment Kyprolis gains NICE approval

NICE has recommended Amgen’s multiple myeloma treatment Kyprolis, a next generation drug which has shown itself superior to Janssen’s standard treatment Velcade.

Sanofi’s blockbuster-tipped Dupixent set for European launch...

After a year's delay, BMS seals Opdivo lung cancer deal with...

Roche hails 4 year NICE access deal for Gazyvaro

Will UK patients get access to novel drugs?

Lilly’s sarcoma drug Lartruvo recommended via Cancer Drugs F...

Amgen’s myeloma treatment Kyprolis gains NICE approval

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

UK market access

Editor's Picks